Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing

Molecular and clinicopathological characteristics of ROS1‐rearranged non‐small‐cell lung cancers identified by next‐generation sequencing

ROS1 gene rearrangements have been reported in diverse cancer types including non‐small‐cell lung cancer (NSCLC), and with a notably higher prevalence in lung adenocarcinoma. The tyrosine kinase inhibitors, crizotinib, lorlatinib, and entrectinib, have demonstrated favorable efficacy in treating ROS...

Full description

Bibliographic Details
Main Authors: Meiying Cui, Yuchen Han, Pan Li, Jianying Zhang, Qiuxiang Ou, Xiaoling Tong, Ruiying Zhao, Nan Dong, Xue Wu, Wencai Li, Guozhong Jiang
Format: Article
Language:English
Published: Wiley 2020-11-01
Series:Molecular Oncology
Subjects:
crizotinib
gene fusion
next‐generation sequencing
non‐small‐cell lung cancer
ROS1
Online Access:https://doi.org/10.1002/1878-0261.12789

Internet

https://doi.org/10.1002/1878-0261.12789

Similar Items